SUPPLEMENTARY TABLES

Supplementary Table 3. Clinical data statistics for the whole set, test set and training set.

Variable	Whole	Test set	Training set
n	501	250	251
PFI (%)			
0	449 (89.6)	225 (90.0)	224 (89.2)
1	52 (10.4)	25 (10.0)	27 (10.8)
Age (mean (SD))	47.34 (15.85)	47.76 (15.73)	46.92 (15.99)
Gender (%)			
Female	366 (73.1)	180 (72.0)	186 (74.1)
Male	135 (26.9)	70 (28.0)	65 (25.9)
T (%)			
T1	142 (28.3)	77 (30.8)	65 (25.9)
T2	164 (32.7)	82 (32.8)	82 (32.7)
T3	170 (33.9)	78 (31.2)	92 (36.7)
T4	23 (4.6)	13 (5.2)	10 (4.0)
TX	2 (0.4)	0 (0.0)	2 (0.8)
M (%)			
Unknown	1 (0.2)	1 (0.4)	0 (0.0)
M0	282 (56.3)	148 (59.2)	134 (53.4)
M1	9 (1.8)	3 (1.2)	6 (2.4)
MX	209 (41.7)	98 (39.2)	111 (44.2)
N **(%)**			
N0	229 (45.7)	127 (50.8)	102 (40.6)
N1	222 (44.3)	103 (41.2)	119 (47.4)
NX	50 (10.0)	20 (8.0)	30 (12.0)
Stage (%)			
Unknown	2 (0.4)	1 (0.4)	1 (0.4)
Stage I	281 (56.1)	139 (55.6)	142 (56.6)
Stage II	52 (10.4)	28 (11.2)	24 (9.6)
Stage III	111 (22.2)	53 (21.2)	58 (23.1)
Stage IV	55 (11.0)	29 (11.6)	26 (10.4)

Supplementary Table 4. The siRNA sequences used in this study are as follows.

siRNA name	siRNA sequence	
	Sense (5′-3′)	Antisense (5′-3′)
siNMU#1	5′-GAACAAGAACUACAAUUGUUU-3′	5′-ACAAUUGUAGUUCUUGUUCUG-3′
siNMU#2	5′-GCCGUAUAGUGAUGGAGAUUU-3′	5′-AUCUCCAUCACUAUACGGCAA-3′

The sequence of Negative control (NC) group of siRNA was provided by Tsingke.

Supplementary Table 5. Primer sequences used for RT-qPCR in this study.

Gene name	Primer sequence	
	Forward Primer	Reverse Primer
β-actin	CCCAGCCATGTACGTTGCTA	TCACCGGAGTCCATCACGAT
NMU	CTCAGGCATCCAACGCACT	GACTTGCCCAACTTCTGTGTC